CLINICAL TRIALS PROFILE FOR VABORBACTAM
✉ Email this page to a colleague
Clinical Trials for Vaborbactam
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT02166476 ↗ | Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP | Completed | Department of Health and Human Services | Phase 3 | Meropenem-vaborbactam is being compared to piperacillin-tazobactam in the treatment of adults with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP). |
NCT02166476 ↗ | Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP | Completed | Melinta Therapeutics, Inc. | Phase 3 | Meropenem-vaborbactam is being compared to piperacillin-tazobactam in the treatment of adults with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP). |
NCT02166476 ↗ | Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP | Completed | Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) | Phase 3 | Meropenem-vaborbactam is being compared to piperacillin-tazobactam in the treatment of adults with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Vaborbactam
Condition Name
Clinical Trial Locations for Vaborbactam
Trials by Country
Clinical Trial Progress for Vaborbactam
Clinical Trial Phase
Clinical Trial Sponsors for Vaborbactam
Sponsor Name
Sponsor Name | |
Sponsor | Trials |
Department of Health and Human Services | 3 |
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) | 3 |
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) | 3 |
[disabled in preview] | 0 |
This preview shows a limited data set Subscribe for full access, or try a Trial |